Volume 31, Number 6—June 2025
CME ACTIVITY - Synopsis
Multicenter Retrospective Study of Spiroplasma ixodetis Infantile Cataract in 8 Countries in Europe
Table
Common clinical manifestations documented in multicenter retrospective study of Spiroplasma ixodetis infantile cataract in 8 countries in Europe that should prompt the clinician to consider a diagnosis of S. ixodetis–related infantile cataract with uveitis*
Clinical manifestation in eyes (%) | Characteristics (%) | Additional comments |
---|---|---|
Lens opacity (100), can be highly asymmetric |
Bilateral (55.6) | NA |
Unilateral (44.4) | NA | |
Progressive over time (46.4) | NA | |
White lens opacity (35.7) | NA | |
Abnormal lens anatomy (25) |
Fibrous plaque, fibrovascular membranes, improperly formed lens |
|
Anterior uveitis (96.4), can be highly asymmetric |
Extensive posterior synechiae (96.4) | May lead to the full seclusion of the pupil and increased intraocular pressure with enlarged corneal diameter |
Large endothelial precipitates (89.3) | Peculiar shape over the entire surface of the cornea | |
Dilated immature iris vessels (71.4) | Can be adherent to the anterior lens capsule or to a pupillary membrane | |
Pupillary membranes (50) | NA | |
Involvement of the posterior segment (14.3) |
Inflammation, retinal scars |
|
Elevated intraocular pressure* (42.8) | Preoperative (14.3) | NA |
Postoperative (25) | NA | |
Pre and postoperative (3.6) | NA | |
Requiring glaucoma surgery (14.3) | NA |
*We defined elevated intraocular pressure as the need for treatment for increased eye pressure on the basis of the treating physicians clinical judgement. NA, not applicable.
1These senior authors contributed equally to this article.
2Additional members of the Spiroplasma Infantile Cataract Group who contributed data are listed at the end of this article.
Page created: April 23, 2025
Page updated: May 28, 2025
Page reviewed: May 28, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.